Clinical trials: Vaccine Prophylaxis
Respiratory Syncytial Viral Infections
Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine
The study is a double-blind (within dose level), placebo-controlled Phase I study to assess the safety, reactogenicity and tolerability of two intranasal dose levels of SynGEM®: a low dose level (140 μg F-protein/2mg BLPs) and a…
- Trial name
- SynGEM (NCT02958540)
- Testing
- SynGEM
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mucosis BV
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198102
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Shigellosis
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
This Phase 1 clinical trial is aimed to evaluate the safety and immunogenicity of 3 doses of 5 sequentially escalating dosages of a candidate vaccine against Shigella sonnei (1790GAHB vaccine) administered by intramuscular route…
- Trial name
- NCT02017899
- Testing
- S. sonnei 1790GAHB
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GSK Vaccines Institute For Global Health S.r.l.
Diarrhea
Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)
This is a Phase II b, double-blind, randomized, placebo-controlled study in healthy adults (age 18-65 years) to evaluate the safety, immunogenicity, different diagnostic tools and efficacy of ETVAX.
- Trial name
- NCT03729219
- Testing
- E. coli ETVAX
- Where
- Finland
- Volunteers
- 749 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Respiratory Syncytial Virus
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
This study will be the first assessment of the efficacy of MEDI7510 for the prevention of respiratory syncytial virus (RSV) disease. It will also provide estimates of vaccine efficacy and of endpoint incidence in the placebo arm.
- Trial name
- NCT02508194
- Testing
- MEDI7510, IIV
- Where
- 61 sites in United States, Canada and 5 more
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Human Papillomavirus Infection
The Effect of Health Belief Model-Based Education and Motivational Interviewing on HPV (Human Papilloma Virus) Knowledge and Vaccine Awareness in Women
This study aims to evaluate the effect of an educational intervention based on the Health Belief Model (HBM) combined with motivational interviewing on women's knowledge about Human Papillomavirus (HPV) infection and their…
- Trial name
- HPV (NCT07097766)
- Testing
- "HBM-Based Education and Motivational Interviewing"
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Infections, Meningococcal, Meningitis, Meningococcic
Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine
Hypothesis: Lower doses of each A/C/Y/W135 component of the meningococcal polysaccharide vaccine could confer a similar functional immunogenic response as the dose of 50 μg currently being used, and subsequently be equally…
- Trial name
- NCT00271479
- Testing
- A, C, Y, W135 meningococcal polysaccharide vaccine
- Where
- 2 sites in Norway, Uganda
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Epicentre
COVID-19
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…
- Trial name
- SCB-2019 (NCT04672395)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, SCB-2019 vaccine
- Where
- 31 sites in Belgium, Brazil and 3 more
- Volunteers
- 31,454 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Influenza, Organ Transplantation
Reducing the Burden of Influenza After Solid-Organ Transplantation
Influenza is associated with significant morbidity and mortality in solid-organ transplant (SOT) recipients and it is mainly prevented by seasonal influenza vaccination.
- Trial name
- STOP-FLU (NCT03699839)
- Testing
- High-dose influenza vaccine, MF59-adjuvanted influenza vaccine, Standard intramuscular influenza vaccine
- Where
- 9 sites in Spain, Switzerland
- Volunteers
- 619 people
- Sponsor
- Oriol Manuel
Rabies Post-exposure Prophylaxis
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
- Trial name
- NCT00345319
- Testing
- rabies vaccine
- Where
- China
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Anthrax
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent…
- Trial name
- NCT07268612
- Testing
- CYFENDUS
- Volunteers
- 250 people
- Sponsor
- Emergent BioSolutions
COVID-19 Infection
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection.
- Trial name
- NCT04639466
- Testing
- Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- Where
- 3 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- GeoVax, Inc.
Meningococcal Disease
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine
The proposed study V72P9E1 is an Extension Study of V72P9. The objectives of this extension study will be to explore antibody persistence in children at approximately 40 months of age and to evaluate the safety, tolerability and…
- Trial name
- NCT01026974
- Testing
- rMenB, rMenB+OMV NZ
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infections, Meningococcal
Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of 3 doses of the meningococcal serogroup B vaccine when given, using either a 0-2-4 month or a 0-1-6 month schedule, to healthy adolescents…
- Trial name
- NCT00137917
- Testing
- Meningococcal serogroup B vaccine
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infection Prevention
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
This is a randomized, observer-blinded, placebo-controlled Phase Ⅱ clinical trial to evaluate the immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
- Trial name
- NCT07208461
- Testing
- Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Prevention of Meningococcal Disease
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
The purpose of this study is to evaluate the safety, immunogenicity and induction of immune memory after two or three doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy infants.
- Trial name
- NCT00262002
- Testing
- MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation), MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation), MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Covid19
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- NCT04564716
- Testing
- Gam-COVID-Vac
- Where
- 8 sites in Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Streptococcus Pneumoniae Vaccines
Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.
Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis.
- Trial name
- NCT00307008
- Testing
- Pneumovax 23™
- Where
- 5 sites in Sweden
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Respiratory Papillomatosis
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening condition resulting in surgical interventions.
- Trial name
- NCT01995721
- Testing
- 4-valent HPV vaccine
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- National Institute of Child Health, Hungary
Human Papilloma Virus, Cervical Cancer
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention
The project aims to increase HPV vaccination and cervical cancer screening through a web-based mobile health education program called, Wheel of Wellness (WoW) and a brief negotiated interview (BNI).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Human Papillomavirus Infection, Oropharyngeal Cancer
- Trial name
- NCT03346915
- Testing
- WoW and BNI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center